Lucid Diagnostics Revenue vs. Net Income

LUCD Stock  USD 0.79  0.02  2.60%   
Based on Lucid Diagnostics' profitability indicators, Lucid Diagnostics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Lucid Diagnostics' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2010-12-31
Previous Quarter
2.4 M
Current Value
2.5 M
Quarterly Volatility
866.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Lucid Diagnostics' Days Of Sales Outstanding is projected to slightly decrease based on the last few years of reporting. At present, Lucid Diagnostics' Change To Netincome is projected to increase significantly based on the last few years of reporting.
For Lucid Diagnostics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lucid Diagnostics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lucid Diagnostics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lucid Diagnostics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lucid Diagnostics over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.12)
Revenue Per Share
0.09
Quarterly Revenue Growth
0.497
Return On Assets
(1.01)
Return On Equity
(10.08)
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Lucid Diagnostics Net Income vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Lucid Diagnostics's current stock value. Our valuation model uses many indicators to compare Lucid Diagnostics value to that of its competitors to determine the firm's financial worth.
Lucid Diagnostics is rated below average in revenue category among its peers. It is rated below average in net income category among its peers . At present, Lucid Diagnostics' Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lucid Diagnostics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Lucid Revenue vs. Competition

Lucid Diagnostics is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 4.83 Billion. Lucid Diagnostics adds roughly 2.43 Million in revenue claiming only tiny portion of equities under Health Care industry.

Lucid Net Income vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Lucid Diagnostics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
2.43 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Lucid Diagnostics

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(52.67 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Lucid Net Income Comparison

Lucid Diagnostics is currently under evaluation in net income category among its peers.

Lucid Diagnostics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Lucid Diagnostics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lucid Diagnostics will eventually generate negative long term returns. The profitability progress is the general direction of Lucid Diagnostics' change in net profit over the period of time. It can combine multiple indicators of Lucid Diagnostics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-16.8 B-17.6 B
Net Loss-50.6 M-48 M
Operating Income-48.5 M-46.1 M
Net Loss-56.8 M-53.9 M
Income Before Tax-52.7 M-50 M
Total Other Income Expense Net-3.8 M-3.6 M
Net Loss-52.7 M-50 M
Income Tax Expense2.3 M2.4 M
Net Interest Income-108 K-113.4 K
Interest Income424 K281.6 K
Change To Netincome15.9 M16.7 M
Net Loss(1.26)(1.32)
Income Quality 0.62  0.42 
Net Income Per E B T 0.92  0.82 

Lucid Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Lucid Diagnostics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lucid Diagnostics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lucid Diagnostics' important profitability drivers and their relationship over time.

Use Lucid Diagnostics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lucid Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lucid Diagnostics will appreciate offsetting losses from the drop in the long position's value.

Lucid Diagnostics Pair Trading

Lucid Diagnostics Pair Trading Analysis

The ability to find closely correlated positions to Lucid Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lucid Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lucid Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lucid Diagnostics to buy it.
The correlation of Lucid Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lucid Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lucid Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lucid Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Lucid Diagnostics position

In addition to having Lucid Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Diversified Assets Thematic Idea Now

Diversified Assets
Diversified Assets Theme
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:
Check out Correlation Analysis.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
To fully project Lucid Diagnostics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lucid Diagnostics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lucid Diagnostics' income statement, its balance sheet, and the statement of cash flows.
Potential Lucid Diagnostics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Lucid Diagnostics investors may work on each financial statement separately, they are all related. The changes in Lucid Diagnostics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lucid Diagnostics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.